|
REVLIMID® AS FIRST-LINE TREATMENT FOR NON-TRANSPLANT ELIGIBLE MYELOMA PATIENTS NOW FUNDED IN ALBERTA AND SASKATCHEWAN
Myeloma Canada is pleased to announce that both Alberta and Saskatchewan have agreed to fund Revlimid ® (lenalidomide) as a first-line treatment for newly-diagnosed myeloma patients who are not eligible for high-dose chemotherapy (also known as autologous stem cell transplant).
Over a year ago, Myeloma Canada made a patient submission to pCODR to advocate for access for this new indication which resulted in a positive recommendation by the committee several months later.
These are the conditions for funding in the respective provinces:
Saskatchewan
The Saskatchewan Cancer Agency announced that as of October 26
th, 2016, the Saskatchewan Cancer funding would be based on the following criteria:
As an option for first line treatment of patients with multiple myeloma who are not eligible for autologous stem cell transplantation. Treatment is in combination with dexamethasone for patients with an ECOG performance status of less than or equal to 2 and continued until disease progression.
This information is publicly available on their website
HERE
Alberta
Alberta Health Services announced that as of October 18
th, 2016, funding would be based on the following criteria:
Lenalidomide as an option for first line treatment in patients with multiple myeloma who are not eligible for autologous stem cell transplantation. Treatment should be in combination with dexamethasone for patients with ECOG PS < 2 and until disease progression.
This information is publicly available on their website HERE
|
